| May 9 |
Peering Into Jaguar Health's Recent Short Interest
|
| May 8 |
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
|
| May 6 |
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
|
| May 3 |
Why Apple Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
|
| Apr 29 |
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
|
| Apr 22 |
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
|
| Apr 18 |
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
|
| Apr 16 |
Jaguar stock rallies 54% on licensing deal for chemo support drug
|
| Apr 16 |
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
|
| Apr 10 |
S&P 500 Down 1%; Delta Air Lines Posts Upbeat Earnings
|
